Literature DB >> 15892687

Antitumour quinones.

C Asche1.   

Abstract

Quinones still comprise one of the largest classes of antitumour agents. For example, the anthracycline antibiotics are among the most utilised anticancer agents ever developed. Many other quinones were tested for their anticancer activity. Though there are general and well-established mechanisms for quinone toxicity, the exact contribution of the quinone moiety to the cytotoxic effect remains frequently uncertain. However, DNA represents the main target for quinoid antitumour agents and most of them belong to the groups of DNA intercalating and/or alkylating agents. But also other cellular structures such as heat shock protein 90 or telomerase have been identified as targets for quinoid compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892687     DOI: 10.2174/1389557053765556

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  23 in total

1.  Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines.

Authors:  Yasmine M Kanaan; Douglas F White; Jharna R Das; Solomon Berhe; Oladapo Bakare; Hillaire Kenguele; Desta Beyene; Yanfei Zhou; Agnes A Day; Robert L Copeland
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

2.  Structural determinant of chemical reactivity and potential health effects of quinones from natural products.

Authors:  Tingting Tu; Daryl Giblin; Michael L Gross
Journal:  Chem Res Toxicol       Date:  2011-08-02       Impact factor: 3.739

3.  Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.

Authors:  Yakini Brandy; Innocent Ononiwu; Dolapo Adedeji; Vonetta Williams; Claudia Mouamba; Yasmine Kanaan; Robert L Copeland; Dwayne A Wright; Ray J Butcher; Samuel R Denmeade; Oladapo Bakare
Journal:  Invest New Drugs       Date:  2011-01-18       Impact factor: 3.850

4.  Aminequinone-hydroxylquinoneimine tautomeric equilibrium revisited: molecular modeling study of the tautomeric equilibrium and substituent effects in 4-(4-R-phenylamino)naphthalene-1,2-diones.

Authors:  Thaís P Fragoso; José Walkimar de Mesquita Carneiro; Maria D Vargas
Journal:  J Mol Model       Date:  2009-09-13       Impact factor: 1.810

5.  Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.

Authors:  Maria F Mendoza; Nicole M Hollabaugh; Suraj U Hettiarachchi; Robin L McCarley
Journal:  Biochemistry       Date:  2012-09-28       Impact factor: 3.162

6.  Balance of beneficial and deleterious health effects of quinones: a case study of the chemical properties of genistein and estrone quinones.

Authors:  Qiang Zhang; Tingting Tu; D André d'Avignon; Michael L Gross
Journal:  J Am Chem Soc       Date:  2009-01-28       Impact factor: 15.419

7.  Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.

Authors:  Brian T Kalet; Meagan B McBryde; Joaquin M Espinosa; Tad H Koch
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

Review 8.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

9.  Protective effect of melatonin against mitomycin C-induced genotoxic damage in peripheral blood of rats.

Authors:  S Ortega-Gutiérrez; M López-Vicente; F Lostalé; L Fuentes-Broto; E Martínez-Ballarín; J J García
Journal:  J Biomed Biotechnol       Date:  2009-10-20

10.  Synthesis and characterization of novel unsymmetrical and symmetrical 3-halo- or 3-methoxy-substituted 2-dibenzoylamino-1,4-naphthoquinone derivatives.

Authors:  Yakini Brandy; Nailah Brandy; Emmanuel Akinboye; Malik Lewis; Claudia Mouamba; Seshat Mack; Ray J Butcher; Alan J Anderson; Oladapo Bakare
Journal:  Molecules       Date:  2013-02-04       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.